Breaking News Instant updates and real-time market news.

HRTX

Heron Therapeutics

$40.10

9.4 (30.62%)

15:04
06/21/18
06/21
15:04
06/21/18
15:04

Heron Therapeutics price target raised to $66 from $42 at Needham

Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company announced positive topline results from two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation.

  • 21

    Jun

  • 26

    Jun

  • 27

    Jun

HRTX Heron Therapeutics
$40.10

9.4 (30.62%)

05/17/18
JEFF
05/17/18
NO CHANGE
Target $38
JEFF
Buy
Heron upcoming Phase IIb data likely positive, says Jefferies
Jefferies analyst Biren Amin believes Heron Therapeutics' HTX-011 Phase IIb study in total knee arthroplasty is "poised for success." The analyst anticipates a positive outcome on the late Q2 readout. On positive data, the shares will likely rally 15%-20%, Amin tells investors in a research note. He sees downside of 10% if the study misses statistical significant but is still clinically relevant. The analyst keeps a Buy rating on Heron with a $38 price target.
06/21/18
EVER
06/21/18
NO CHANGE
Target $80
EVER
Outperform
Heron Therapeutics price target raised to $80 from $56 at Evercore ISI
Evercore ISI analyst Josh Schimmer raised his price target on Heron Therapeutics to $80 from $56 after the company announced positive topline results from two Phase 2b studies of HTX-011.
06/21/18
06/21/18
NO CHANGE
Target $80

Outperform
Heron Therapeutics price target raised to $80 on positive HTX-011 results at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer raised his price target for Heron Therapeutics to $80 from $56 after the company reported data from its two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation. The analyst notes that these were primarily for procuring a broad post-surgical label based on the highly compelling Phase 3 studies of the product in bunionectomy and hernia repair by demonstrating safety and predictable PK. HTX-011 not only demonstrated the required safety and PK profile to support a broad label, but the results showed clear clinical benefit over both placebo and bupivacaine, Schimmer adds. The analyst reiterates an Outperform rating on the shares.
06/21/18
CANT
06/21/18
NO CHANGE
Target $40
CANT
Overweight
Cantor has $59 per share 'bull case scenario' for Heron Therapeutics
Cantor Fitzgerald analyst Louise Chen says the positive data announced this morning by Heron Therapeutics will support the new drug application filing for HTX-011 and expand the commercial opportunity for the drug. The analyst continues to believe that the peak sales potential for HTX-011 is being underappreciated. She has a $40 price target on the shares with a $59 "bull case scenario." Chen keeps an Overweight rating on Heron Therapeutics. The stock in morning trading is up 30% to $39.82.

TODAY'S FREE FLY STORIES

UFPI

Universal Forest

$38.35

-0.205 (-0.53%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
Universal Forest reports Q2 EPS 71c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLG

SL Green Realty

$100.51

0.29 (0.29%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
SL Green Realty reports Q2 FFO $1.69, consensus $1.68 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ICFI

ICF International

$72.50

-0.5 (-0.68%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Hot Stocks
ICF International awarded infrastructure contract by LA County Public Works »

ICF has been selected by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TCBI

Texas Capital

$94.00

2.2 (2.40%)

16:06
07/18/18
07/18
16:06
07/18/18
16:06
Earnings
Texas Capital reports Q2 EPS $1.38, consensus $1.39 »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

IBM

IBM

$144.32

0.86 (0.60%)

16:06
07/18/18
07/18
16:06
07/18/18
16:06
Earnings
IBM reports Q2 cognitive solutions revenue $4.6B, flat y/y »

Reports Q2 global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

IBM

IBM

$144.32

0.86 (0.60%)

16:05
07/18/18
07/18
16:05
07/18/18
16:05
Hot Stocks
IBM says strategic imperatives revenue was $39B over last 12 months »

Strategic imperatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

PTC

PTC

$98.13

-0.78 (-0.79%)

16:05
07/18/18
07/18
16:05
07/18/18
16:05
Earnings
PTC sees FY18 EPS $1.41-$1.46, consensus $1.39 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DWCH

Datawatch

$11.30

-0.3 (-2.59%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
Datawatch reports Q3 EPS 7c, consensus (5c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 16

    Aug

PFBC

Preferred Bank

$63.93

0.18 (0.28%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
Preferred Bank reports Q2 EPS $1.14, consensus $1.09 »

Q2 net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Sep

  • 07

    Nov

IBM

IBM

$144.39

0.93 (0.65%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
IBM backs FY18 adjusted EPS view of 'at least' $13.80, consensus $13.78 »

Operating diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

ORRF

Orrstown Financial

$25.60

-0.5 (-1.92%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
Orrstown Financial reports Q2 EPS 48c, consensus 39c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$98.28

-0.63 (-0.64%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
PTC sees Q3 EPS 41c-46c, consensus 41c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

IBM

IBM

$144.32

0.86 (0.60%)

16:03
07/18/18
07/18
16:03
07/18/18
16:03
Earnings
IBM reports Q2 operating EPS $3.08, consensus $3.04 »

Reports Q2 revenue $20B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

CP

Canadian Pacific

$189.21

3.205 (1.72%)

16:03
07/18/18
07/18
16:03
07/18/18
16:03
Hot Stocks
Breaking Hot Stocks news story on Canadian Pacific »

Canadian Pacific reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PTC

PTC

$98.28

-0.63 (-0.64%)

16:03
07/18/18
07/18
16:03
07/18/18
16:03
Hot Stocks
PTC reports Q3 deferred revenue $1.21B, up 33% »

Third quarter license and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CP

Canadian Pacific

$189.21

3.205 (1.72%)

16:03
07/18/18
07/18
16:03
07/18/18
16:03
Hot Stocks
Canadian Pacific CEO says 'well positioned for a strong second half' »

"Overall, it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CP

Canadian Pacific

$189.16

3.155 (1.70%)

16:02
07/18/18
07/18
16:02
07/18/18
16:02
Hot Stocks
Canadian Pacific reports Q2 operating ratio 64.2% »

An increase of 140 basis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PTC

PTC

$98.33

-0.58 (-0.59%)

16:02
07/18/18
07/18
16:02
07/18/18
16:02
Earnings
PTC reports Q3 adjusted EPS 36c, consensus 32c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CP

Canadian Pacific

$189.17

3.165 (1.70%)

16:01
07/18/18
07/18
16:01
07/18/18
16:01
Earnings
Canadian Pacific reports Q2 adjusted EPS C$3.16, consensus C$3.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CVCY

Central Valley Community

$21.15

-0.05 (-0.24%)

16:01
07/18/18
07/18
16:01
07/18/18
16:01
Earnings
Central Valley Community reports Q2 EPS 36c, consensus 34c »

"The second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMI

Foundation Medicine

$136.83

(0.00%)

16:00
07/18/18
07/18
16:00
07/18/18
16:00
Hot Stocks
Foundation Medicine to settle patent infringement suit with Guardant Health »

Foundation Medicin and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

VR

Validus

$67.99

(0.00%)

15:57
07/18/18
07/18
15:57
07/18/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Validus 

Validus trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$20.00

-1.6 (-7.41%)

15:55
07/18/18
07/18
15:55
07/18/18
15:55
Options
Cara Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

NCLH

Norwegian Cruise Line

$50.01

2.43 (5.11%)

15:40
07/18/18
07/18
15:40
07/18/18
15:40
Options
Norwegian Cruise Lines options volume is 27X daily average as shares rally »

Norwegian Cruise Lines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$17.77

0.08 (0.45%)

15:34
07/18/18
07/18
15:34
07/18/18
15:34
Options
Kinder Morgan options imply 4.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.